ABSTRACT
Safety assessment is a critical part of drug development. In analyzing the safety data from clinical trials and observational studies, a number of statistical difculties arise. Although demonstrating both safety and efcacy is required for the drug regulatory approval, the use of advanced statistical methods in evaluating safety data has not received as much attention as evaluating efcacy.
